This Article Full Text (PDF) All Versions of this Article: 1756285609338501v1 1756285609338501v2 2/5/313    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Bermejo, P. E. Articles by Anciones, B. Social Bookmarking                         What's this?

Review: A review of the use of zonisamide in Parkinson’s disease

Sanatorio Nuestra Señora del Rosario - Hospital Sanitas La Zarzuela, Madrid, Spain, pedro_bermejo{at}hotmail.com

Buenaventura Anciones

Sanatorio Nuestra Señora del Rosario - Hospital Sanitas La Zarzuela, Madrid, Spain

Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine, neuropathic pain, essential tremor and various psychiatric diseases. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson’s disease. In addition, other studies support the utility of zonisamide in other symptoms of this disease. The therapeutic doses of zonisamide for the treatment of Parkinson’s disease are considerably lower than those for the treatment of epilepsy. This antiepileptic drug has been used in Japan for more than 15 years and so it is expected that it will be safe and well tolerated in patients with Parkinson’s disease. However, the pharmacological mechanisms of the antiparkinsonian actions of zonisamide remain unclear and more basic investigation is warranted. The aim of this paper is to review the structure, mechanisms of action, pharmacokinetics and antiparkinsonian action of zonisamide.

Key Words: antiepileptic • neuromodulator • Parkinson’s disease • zonisamide

This version was published on September 1, 2009

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 5, 313-317 (2009)
DOI: 10.1177/1756285609338501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?